MacroGenics | MGNX - Pre Tax Profit

Stock Price
1.78
Daily Change
-0.23 -11.25%
Monthly
20.75%
Yearly
-48.55%
Q3 Forecast
1.98

MacroGenics reported $-36150000 in Pre-Tax Profit for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 245.42M
Cash and Equivalent USD 130.69M
Cost of Sales USD 49.7M
Current Assets USD 204.94M
Current Liabilities USD 39M
Debt USD 37.25M
EBIT USD -35.34M
EBITDA USD -33.44M
Employees 339
EPS Earnings Per Share USD -0.57
Equity Capital and Reserves USD 46.62M
Gross Profit on Sales USD -27.46M
Interest Expense on Debt USD 802K
Interest Income USD 1.41M
Loan Capital USD 70.26M
Market Capitalization USD 124.9M
Net Income USD -36.25M
Operating Expenses USD 59M
Operating Profit USD -36.76M
Ordinary Share Capital USD 63.21M
Pre-Tax Profit USD -36.15M
Sales Revenues USD 22.24M
Selling and Administration Expenses USD 9.3M
Stock USD 9.28M
Trade Creditors USD 4.66M
Trade Debtors USD 12.53M

Pre Tax Profit Change Date
AbbVie USD 1.66B 3.15B Mar/2025
Amgen USD 1.57B 405M Jun/2025
AstraZeneca USD 3.13B 275M Jun/2025
Biogen USD 744M 432.8M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Daiichi Sankyo JPY 105.44B 24.81B Jun/2025
Eli Lilly USD 6.78B 3.32B Jun/2025
Genmab DKK 423M 179M Jun/2025
Geron USD -16375000 3.46M Jun/2025
Gilead Sciences USD 2.43B 780M Jun/2025
J&J USD 13.63B 8.21B Mar/2025
MacroGenics USD -36150000 21.67M Jun/2025
Merck USD 6.77B 864M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Roche Holding CHF 1.78B 2.33B Dec/2024
Xencor USD -31075000 17.19M Jun/2025